DEXCOM, INC.

Lobbying for DEXCOM, INC.

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 20, 2026

Expenses

$320,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

California

Official filing document

Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 3

Trade (domestic/foreign)

Issues related to global supply chains Issues related to the Administration's Executive Orders

Health Issues

CGM Coverage policy Issues related to sterilization of medical devices Issues related to medical device electronic labeling H.R.1539, Medical Device Electronic Labeling Act Issues related to artificial intelligence and other machine learning advances in healthcare Issues related to advances in diabetes technology Issues related to CY 2026 rulemaking

Medicare/Medicaid

CGM Coverage policies Issues related to breakthrough technology

Bills named in this filing 1

H.R. 1539
Medical Device Electronic Labeling Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.